依达拉奉联合免疫三氧治疗急性脑梗死患者的疗效

Efficacy of Edaravone Combined with Immune Trioxygen in the Treatment of Acute Cerebral Infarction

目的探究急性脑梗死患者采用依达拉奉与免疫三氧联合治疗的临床效果。方法选取2019年1~12月本院经头颅MRI等影像学检查确诊的84例急性脑梗死患者,按照双盲法分为对照组和试验组,每组42例。对照组予以依达拉奉治疗,试验组予以依达拉奉联合免疫三氧治疗,比较两组患者的治疗总有效率、日常生活能力评分、超敏C反应蛋白水平。结果试验组患者治疗总有效率为92.86%,对照组为73.81%,差异有统计学意义(P<0.05);治疗后,两组患者日常生活能力评分较治疗前高,且试验组治疗后的日常生活能力评分升高幅度比对照组大(P<0.05);治疗后,两组患者超敏C反应蛋白水平低于治疗前,且试验组治疗后的超敏C反应蛋白水平降低幅度比对照组大(P<0.05)。结论针对急性脑梗死患者采用依达拉奉与免疫三氧联合治疗有助于改善超敏C反应蛋白水平,提高其日常生活能力。

Objective To explore the clinical effect of edaravone combined with immune trioxygen on patients with acute cerebral infarction.Methods From January 2019 to December 2019,84 patients with acute cerebral infarction confirmed by head CT and other examinations in our hospital were selected and divided into two groups according to double blind method.The control group was treated with edaravone,while the experimental group was treated with edaravone combined with immune trioxygen.The total effective rate,daily living ability score,serum IL-17 level and high sensitivity C-reactive protein level of the two groups were compared.Results The total effective rate of patients in the control group was 73.81%,which was statistically significant compared with 92.86%in the experimental group(P<0.05).After treatment,the scores of daily living ability in the two groups were higher than before treatment,and the scores in the experimental group were higher than those in the control group(P<0.05).After treatment,the level of hypersensitive C-reactive protein in the two groups was lower than that before treatment,and the reduction level of score in the experimental group after treatment was higher than that in the control group(P<0.05).Conclusion Edaravone combined with immune trioxygen can improve the level of high sensitivity C-reactive protein in patients with acute cerebral infarction,and improve their daily living ability.